Amgen announces positive results from two Phase 3 BLINCYTO ® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia

0
14

[ad_1]

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared to conventional consolidation chemotherapy in pediatric patients with

Source: World Pharma NewsCategory: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Related Links:

Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackgroundThe optimal the conditioning regimens for allogeneic hematopoietic stem-cell transplantation, especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1562 myeloablative conditioning and 2693 nonmyeloablative conditioning groups, the ove…

Conclusion: This case demonstrates the importance of a broad differential diagnosis for a child presenting with leg pain and fever.
PMID: 31528139 [PubMed]

Source: Ochsner JournalCategory: General Medicine Tags: Ochsner J Source Type: research

A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare.
This news may affect mesothelioma patients in the future.
Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer.
The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is…

Publication date: Available online 15 September 2019Source: Advances in Biological RegulationAuthor(s): Samuel Gusscott, Francesco Tamiro, Vincenzo Giambra, Andrew P. WengAbstractT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer, characterized by an uncontrolled expansion and accumulation of T-cell progenitors. During leukemic progression, immature T cells grow abnormally and occupy the bone marrow compartment, thereby interfering with the production of normal blood cells. Pediatric T-ALL is curable with intensive chemotherapy, but there are significant, long-term side effects and ∼20% of patients suf…

ABSTRACT
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic cancer derived from the malignant transformation of T-cell progenitors. Outcomes remain poor for T-ALL patients who have either primary resistance to standard-of-care chemotherapy or disease relapse. Notably, there are currently no targeted therapies available in T-ALL. This lack of next-generation therapies highlights the need for relevant preclinical disease modeling to identify and validate new targets and treatment approaches. Here, we adapted a spontaneously arising, genetically heterogeneous, thymic transplantation-based murine model of…

Source: DMM Disease Models and MechanismsCategory: Biomedical Science Authors: Tags: Cancer RESEARCH ARTICLE Source Type: research

Publication date: November 2019Source: Biomedicine &Pharmacotherapy, Volume 119Author(s): Dongfang Guo, Airong Zhang, Jing Huang, Meifang Suo, Yaping Zhong, Yile LiangAbstractAcute lymphoblastic leukemia (ALL), usually treated with chemotherapy, has limited therapeutic effects and high toxicity. Upregulation of HSP70 induces tumor development, however, the molecular mechanism of HSP70 in ALL remains unclear. In our research, we aimed to investigate the role of HSP70 in ALL, specifically the molecular mechanisms underlying cell apoptosis and proliferation. We found that HSP70 expression in leukomonocytes from ALL patien…

Abstract
Acute lymphoblastic leukemia (ALL), usually treated with chemotherapy, has limited therapeutic effects and high toxicity. Upregulation of HSP70 induces tumor development, however, the molecular mechanism of HSP70 in ALL remains unclear. In our research, we aimed to investigate the role of HSP70 in ALL, specifically the molecular mechanisms underlying cell apoptosis and proliferation. We found that HSP70 expression in leukomonocytes from ALL patients was increased compared with the control group. HSP70 expression in NALM-6 and BE-13 was also up-regulated contrast with AHH-1. Inhibition of HSP70 significant…

AbstractIntroductionIntussusception, which is common in pediatric patients but rare in adults with leukemia, usually presents with an intralumenal lesion as a lead point in adults.Case reportWe herein report the case of a 38-year-old female who developed right lower quadrant abdominal pain and fever on day 16 of chemotherapy. Abdominal computed tomography showed ileocecal intussusception. The patient underwent surgery, and the definitive pathological diagnosis was typhlitis leading to intussusception. Albeit very rare in adults, typhlitis-induced intussusception should be suspected in those with leukemia presenting with abdominal pain.

Publication date: Available online 30 August 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Andra-Sorina Tatar, Ancuta Jurj, Ciprian Tomuleasa, Adrian Florea, Ioana Berindan-Neagoe, Dana Cialla-May, Juergen Popp, Simion Astilean, Sanda BocaAbstractThe incidence of Acute Lymphoblastic Leukemia (ALL) is increasing globally, and it is being clinically addressed by chemotherapy, followed by immunotherapy and stem cell transplantation, all with potential life-threatening toxicities. In the need for more effective therapeutics, newly developed disease-targeted nanocompounds can thus hold real potential.In this pape…

[ad_2]

Source link